Protein Kinase Inhibitors: all 15,766 studies that test it

Page 136 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)CompletedNCT01220570Phase 1
• A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant GliomaCompletedNCT01220271Phase 1/2
• Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+CompletedNCT01220076Phase 2
• Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell CarcinomaStatus unknownNCT01219751Phase 2
• A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneCompletedNCT01219699Phase 1
• A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.TerminatedNCT01219543Phase 1
• Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast TumorsCompletedNCT01218529Phase 2
• Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic MyopiaWithdrawnNCT01218230Not applicable
• Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive, not recruitingNCT01217931Phase 2
• Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.CompletedNCT01217619Phase 2
• Selumetinib and Cetuximab in Treating Patients With Refractory Solid TumorsCompletedNCT01217450Phase 1
• A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix CancerCompletedNCT01217177Phase 1
• Rapamycin In Angiomyolipomas In Patients With Tuberous SclerosisCompletedNCT01217125Phase 4
• Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue SarcomasStatus unknownNCT01216839Phase 2
• Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed OsteosarcomaStatus unknownNCT01216826Phase 2
• Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic MelanomaTerminatedNCT01216657Phase 2
• Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)TerminatedNCT01216371Phase 2
• An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular EndpointsCompletedNCT01216085Phase 2
• Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate CancerCompletedNCT01215799Phase 2
• Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine TumorsTerminatedNCT01215578Phase 2
• Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar CarcinomaTerminatedNCT01215565Phase 2
• Sorafenib in Urothelium Cancer of BladderTerminatedNCT01215266Phase 2
• Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCCStatus unknownNCT01214343Phase 3
• Study to Assess Safety and Tolerability of AZD4547 in Japanese PatientCompletedNCT01213160Phase 1
• Standard Chemotherapy With of Without Axitinib in Malignant MesotheliomaCompletedNCT01211275Phase 1/2
• A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid TumorsCompletedNCT01210846Phase 1
• Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerStatus unknownNCT01210053Phase 2
• Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib TabletsCompletedNCT01208155Phase 1
• Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line ChemotherapyTerminatedNCT01208064Phase 2/3
• Tasigna in Glivec-resistant or Intolerant Patients in CMLCompletedNCT01206088Phase 4
• CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)CompletedNCT01206036Phase 1/2
• Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast CancerWithdrawnNCT01205217Phase 2
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue SarcomaTerminatedNCT01204450Phase 1
• Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy VolunteersCompletedNCT01204112Phase 1
• Study of PX-866 and Docetaxel in Solid TumorsCompletedNCT01204099Phase 1/2
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT01203943Phase 2
• A Study of Nilotinib in Growing Vestibular SchwannomasTerminatedNCT01201538Phase 2
• Study of CX-4945 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01199718Phase 1
• RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell LymphomasCompletedNCT01198665Phase 1/2
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsCompletedNCT01198184Phase 1
• Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome ResistanceCompletedNCT01197170Phase 1
• Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung CancerCompletedNCT01196234Phase 2
• A Study of BEZ235 in Adult Japanese Patients With Advanced Solid TumorsCompletedNCT01195376Phase 1
• Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced TumoursWithdrawnNCT01194193Phase 1
• RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT01193881Phase 1
• A Study of Apatinib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01192971Phase 2
• PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)CompletedNCT01192308Phase 1
• Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT01192243Phase 2
• Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-PaclitaxelCompletedNCT01192165Phase 1
• Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract CancerCompletedNCT01191892Phase 2
• A Study to Evaluate the Drug Interaction of ASP015K and TacrolimusCompletedNCT01190670Phase 1
• Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer PatientsStatus unknownNCT01189903Phase 2/3
• RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
• A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung CancerTerminatedNCT01188707Phase 1/2
• Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced MalignanciesCompletedNCT01188252Phase 1
• Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung CancerTerminatedNCT01187615Phase 1
• Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATECompletedNCT01187212Phase 2
• Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced CancerActive, not recruitingNCT01187199Phase 1
• Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedNCT01186861Phase 2
• Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy VolunteersCompletedNCT01185184Phase 1
• A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell CarcinomaCompletedNCT01185158Phase 2
• Lapatinib and Cetuximab in Patients With Solid TumorsCompletedNCT01184482Phase 1
• Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)CompletedNCT01183663Phase 1
• An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive RegimensCompletedNCT01183247Phase 4
• A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid TumorsWithdrawnNCT01182883Phase 1
• Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by SurgeryStatus unknownNCT01182272Phase 2
• AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic CancerStatus unknownNCT01182246Phase 1/2
• Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor MalignanciesCompletedNCT01182168Phase 1
• A Study to Assess Drug Interaction of ASP015K and MidazolamCompletedNCT01182077Phase 1
• First-in-Human Single Ascending and Multiple Dose of GLPG0634CompletedNCT01179581Phase 1
• Japanese BAY86-9766 Monotherapy Phase I StudyCompletedNCT01179295Phase 1
• Pazopanib and Paclitaxel for Non-Small Cell Lung CancerWithdrawnNCT01179269Phase 2
• Effect of Supplemental Oral Curcumin in Patients With Atopic AsthmaCompletedNCT01179256Not applicable
• Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers SyndromeWithdrawnNCT01178151Phase 2
• Study of Apatinib in Metastatic Triple-Negative Breast Cancer PatientsCompletedNCT01176669Phase 2
• Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent ChordomaStatus unknownNCT01175109Phase 1
• Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine TumorStatus unknownNCT01175096Phase 1/2
• Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate CancerTerminatedNCT01174199Phase 1
• Efficacy Study of Temsirolimus to Treat Head and Neck CancerCompletedNCT01172769Phase 2
• Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 2
• Primary Chemotherapy in Patients With HER2-positive Early Breast CancerCompletedNCT01172223Phase 1/2
• Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin AmyloidosisCompletedNCT01171859Phase 2
• Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT01170104Phase 2
• Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)WithdrawnNCT01170052Phase 1/2
• Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) DiseaseCompletedNCT01168440Phase 2
• Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Status unknownNCT01168050Phase 2
• Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid TumorsCompletedNCT01168011Phase 1
• Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung CancerCompletedNCT01167530Phase 1
• Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseCompletedNCT01167244Phase 2
• Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedNCT01167166Phase 1/2
• Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsCompletedNCT01165905Phase 1
• Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid TumorsCompletedNCT01165385Phase 1
• Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian CancerCompletedNCT01164995Phase 2
• Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)CompletedNCT01164267Phase 2
• Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid CancerCompletedNCT01164176Phase 2
• INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseCompletedNCT01164163Phase 1
• Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AMLCompletedNCT01161550Phase 1
• A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer PatientsTerminatedNCT01161368Phase 2
• Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY TrialTerminatedNCT01160926Phase 1

← Protein Kinase Inhibitors overview